glp-1 oral reviews Novo applies to FDA for cardio label expansion of Rybelsus FDA approves GLP-1 pill for
Description
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans
Reasonable triggers include: vomiting or diarrhea persisting beyond 24-48 hours, inability to keep down fluids, symptoms of dehydration, muscle weakness interfering with function, or mental status changes
What about Ozempic personality
Regulators are responding to this expansion with increased oversight
doi: 10.1111/ijpo.70024
